A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and osteoarthritis.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

See Also GLP-1s masterfully reduce the amount of inflammation in the body by stimulating weight ... “Novo Nordisk does not ...

Novo Nordisk is working on a new obesity drug that could ... Semaglutide, the GLP-1 drug that Novo sells under the brand ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

A new study shows that Ozempic may help ease arthritis knee pain in people with obesity. Here's what to know about the study and whether semaglutide can truly help reduce knee pain, according to ...

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...